Wednesday, July 31, 2019 Daily Archives

On the biotech doorstep: Why Sartorius moved its bioanalytics to Cambridge

Sartorius Stedim Biotech says it consolidated its cell line and testing solutions in Cambridge, Massachusetts to be close to the industry it serves. Services like analytics, QC and characterization, have traditionally been done inhouse. “It was done by what were referred to at one time as testing houses. These were mostly very large QC labs that focused on QC release for firstly traditional pharma products, but that migrated to the biologics,†Maurice Phelan, site head of Cambridge US, Sartorius Stedim…

Danaher: ‘All indications show GE is in wonderful shape’

Danaher Corporation says customers are excited about the combination of Pall Biotech and GE Biopharma as it moves closer to completing the $21.4 billion acquisition. In February, Danaher announced it had reached an agreement to acquire the biopharma division of GE Healthcare for $21.4 billion (€19.1 billion). Danaher first entered the bioprocess space through its $13.8 billion acquisition of Pall Corporation in 2015. This acquisition will, therefore, make Danaher the largest vendor with a fully end-to-end bioprocessing offering. The deal is…